Solid Tumour Hypoxia

Welcome to ManTRa Diagnostics

At ManTRa DX we are a diagnostics development company that originates from the Department of Translational Radiobiology based within the Manchester Cancer Research Centre.

We are passionate about making major advances with personalised cancer medicine, with a focus on solid tumour hypoxia.

What we know is that solid tumours have different amounts of oxygen and low levels (also known as hypoxia) are often associated with resistance to treatments.

Through extensive research, we have found that the most hypoxic tumours are more likely to come back following surgery and will be resistant to chemotherapy, radiotherapy and immunotherapy.

There is currently no way to measure the level of hypoxia in tumours, so we have developed tumour-site specific gene expression signatures to assess hypoxia. In doing so, we can deliver major advances in personalised cancer medicine. From there, the signatures can then be used to make a more informed choice on the types of treatments available and suitable to the patient.

If you are interested in discussing our technology, please register your interest via our contact form.

In the meantime, you can learn more about us and meet the team, as well as our story and our history.